

*Society for  
Endocrinology*  
**Financial  
Statements  
2019**

---

**SOCIETY FOR ENDOCRINOLOGY**

(A COMPANY LIMITED BY GUARANTEE)

**FINANCIAL STATEMENTS**

For the year ended 31 December 2019

---

# **SOCIETY FOR ENDOCRINOLOGY**

## REPORT OF THE COUNCIL OF MANAGEMENT

---

### **Reference and administrative details of the charity, its Trustees and advisors**

The Society for Endocrinology is a company limited by guarantee, governed in accordance with its Memorandum and Articles of Association.

The administrative information required to be given is as follows:

|   |  |  |
|---|--|--|
| <b>Charity Registration No:</b>         | 266813   | Registered with the Charity Commission for England and Wales |
| <b>Company Registration No:</b>         | 349408   |  |
| <b>Principal and Registered Office:</b> | Starling House<br>1600 Parkway North<br>Bristol BS34 8YU |  |

#### **Council of Management:**

|                         |  |
|-------------------------|--|
| Professor G R Williams  | (President) Resigned 12 November 2019  |
| Professor R V Thakker   | (President) Appointed 12 November 2019 |
| Professor E Davies      | (General Secretary)                    |
| Dr B McGowan            | (Treasurer)                            |
| Professor J H D Bassett | (Programme Secretary)                  |
| Professor R Andrew      | Resigned 12 November 2019              |
| Dr K Boelart            |  |
| Professor S Forbes      | Appointed 12 November 2019             |
| Dr M Freel              | Appointed 12 November 2019             |
| Dr M Gurnell            | Resigned 12 November 2019              |
| Professor M Hewison     | Resigned 12 November 2019              |
| Dr T M Kearney          | Appointed 12 November 2019             |
| Professor G G Lavery    |  |
| Dr D A Rees             |  |
| Professor R Reynolds    |  |
| Professor J W Tomlinson |  |

#### **Senior Staff:**

|               |  |
|---------------|--|
| Mr I Russell  | (Chief Executive & Company Secretary)      |
| Mr D Mills    | (Finance Director)                         |
| Ms L Udakis   | (Director of Membership Engagement)        |
| Ms T Horner   | (HR & Performance Director)                |
| Mr R Cropley  | (Operations Director)                      |
| Mrs K Sargent | (Deputy Managing Director, Bioscientifica) |

No staff are registered as directors of the Society for Endocrinology at Companies House. The term 'director' is used for internal purposes only.

#### **Independent Auditor:**

Haysmacintyre LLP  
10 Queen Street Place  
London  
EC4R 1AG

**SOCIETY FOR ENDOCRINOLOGY**  
REPORT OF THE COUNCIL OF MANAGEMENT

---

**Reference and administrative details of the charity, its Trustees and advisors (continued)**

|                             |  |   |
|-----------------------------|--|---|
| <b>Solicitors:</b>          | Royds Withy King<br>69 Carter Lane<br>London<br>EC4V 5EQ                                     |   |
| <b>Bankers:</b>             | NatWest Bank plc<br>Thornbury Branch<br>PO Box 1369<br>Bristol BS99 5HD                      | HSBC Bank plc<br>27 Gloucester Road North<br>Filton<br>Bristol BS27 0SQ |
| <b>Investment Managers:</b> | Brewin Dolphin Limited<br>2 <sup>nd</sup> Floor<br>5 Callaghan Square<br>Cardiff<br>CF10 5BT |   |

## About us

The Society for Endocrinology (the Society) is the UK home of endocrinology. Endocrinology is the study of the endocrine system – a network of glands producing chemical messengers called hormones that play a vital role in controlling and regulating many functions of living organisms including metabolism, growth and development, sexual function and reproduction, heart rate, and blood pressure. We have around 3,000 members and bring together the global endocrine community to share ideas and advance our discipline. As a membership organisation, we support scientists, clinicians and nurses who work with hormones throughout their careers. We also engage policy-makers, journalists, patients and the public with hormone science to encourage informed health decisions, and to demonstrate the value of endocrinology to the wider world.

It is estimated that 1 in 3 people in the UK are affected by an endocrine-related condition; 25% of the UK population are obese<sup>1</sup>, 7% are living with diabetes<sup>2</sup>, and 4% suffer from osteoporosis<sup>3</sup> - all are endocrine conditions. In addition, around 1 in 7 couples may have difficulty conceiving and there are also a large number of rarer endocrine conditions, including Cushing's disease and acromegaly. Thanks to endocrinologists, diabetes patients are able to lead longer, healthier lives, infertile couples are able to conceive, and those with breast and prostate cancer are increasingly beating the odds.

Together, our members advance the pace of learning and research across the sector from basic science to clinical practice. By sharing our expertise with policy-makers and the public, the Society and our members are helping to shape the future of public health.

## **Our strategy: shaping the future of hormone research and clinical practice**

The Society for Endocrinology exists to advance the understanding of endocrinology. Endocrinology is fundamental to human, animal, and plant life. Hundreds of millions of people worldwide suffer from endocrine conditions... indeed every minute of every day hormones have a direct impact on all of our lives. Our work centres on providing support for cutting edge research which furthers the understanding of the endocrine system, ensuring the latest knowledge is used to improve patient outcomes, and raising public awareness of the impact of hormones so that people can make better healthcare choices. Our members work to gain a better understanding of hormones and the endocrine system which allows us to live happier, healthier, and longer lives; we work to support the needs and priorities of our diverse membership of basic scientists, specialist nurses, and clinicians working in endocrinology and closely related disciplines.

### *Supporting research to extend our understanding*

Endocrinology is a relatively new discipline: new hormones are still being discovered and we are developing our understanding of the complex chemical messaging and feedback schemes that make up endocrine systems.

In 2019 the Society for Endocrinology supported cutting-edge research and training by awarding £396k in grants (see note 8) including £176k Early Career grants used, for example, for researchers to gain preliminary data before applying for other external funding, £128k to support knowledge exchange via attendance at conferences, and £26k to enable students to gain valuable hands-on experience in an active research environment. The Society also runs or supports a number of cutting-edge international scientific meetings throughout the year.

The Society owns five peer-reviewed journals and co-owns another. All six journals publish high-quality research and these journals serve as hubs for knowledge exchange and points of condensation for our exciting discipline.

---

<sup>1</sup> <https://www.nhs.uk/conditions/obesity/>

<sup>2</sup> [https://www.diabetes.org.uk/about\\_us/news/new-stats-people-living-with-diabetes](https://www.diabetes.org.uk/about_us/news/new-stats-people-living-with-diabetes)

<sup>3</sup> <https://www.nhs.uk/conditions/osteoporosis/>

**About us (cont.)**

*Developing best practice in clinical care*

A key component of the Society's work is in developing and sharing best practice in clinical care.

We work with the Association of British Clinical Diabetologists and the Federation of Royal Colleges of Physicians of the United Kingdom to deliver the Specialty Certificate Examination (SCE) in Endocrinology and Diabetes. The SCE is a compulsory component of assessment for the Certificate of Completion of Training for all UK trainees specialising in Endocrinology and Diabetes. We also provide a number of training and networking events, including our flagship SfE BES conference, that ensure that clinical endocrinologists can stay abreast of developments in our fast-moving discipline.

We produce clinical guidance for the management of endocrine conditions for specialists, primary health care workers and first responders. We also organise and deliver audit visits to clinical centres which, along with our guidelines, helps to ensure the adoption of best practice and consistency of care across the country. In addition, the Society manages a programme of UK-wide research projects to better understand rare endocrine conditions and improve patient outcomes.

*Ensuring the public make informed health choices*

Our aim is for everybody to have a better understanding of hormones and to make informed decisions about their health as a result. Endocrinology is a hugely important subject that impacts every living organism and so we also want to inspire young people to take an interest in studying endocrinology and related subjects. In addition to supporting clinical best practice, we work proactively to ensure accurate reporting of endocrinology in the media and promote the understanding and discussion of endocrinology through public events and online resources such as *You and Your Hormones* ([www.yourhormones.info](http://www.yourhormones.info)).

We seek to inform policy and decision makers by promoting the Society's expertise to external bodies, including the NHS, government departments, higher education bodies, and scientific and medical organisations, thus promoting best practice in science and medicine.

We also work closely with patient support groups in endocrinology to improve information and care for patients and carers. The Society makes grants available to fund specific patient group activities (2019 £3,031). We also facilitate communication with the medical community by inviting patient support groups to our events.

*A vibrant community*

Underpinning all of these activities is the important role that the Society plays in ensuring that the endocrine community remains vibrant.

We promote recruitment, retention and training of the best scientists, doctors and nurses in endocrinology to ensure a health talent-pool in the discipline. The Society spends in excess of £500,000 per annum on support to early career endocrinologists and this will continue to be a priority through activities including free access to Career Development Workshops, early career grants, free registration at events, travel grants, summer studentships, and a variety of prizes and awards.

We also recognise and reward success in endocrinology at all levels through an annual programme of medals, prizes and awards.

*Wider networks and collaborations*

The Society recognises that some of its aims can best be achieved by collaboration with other organisations. The Society is a member of the Professional Associations Research Network, Parliamentary and Scientific Committee, the Foundation for Science and Technology, Understanding Animal Research, the Association of Medical Research Charities, the Association of Learned and Professional Society Publishers, and works closely with the Science Media Centre.

### **About us (cont.)**

The Society is also a member of the International Society of Endocrinology and the European Society of Endocrinology (ESE). An alliance has been established with ESE whereby they have adopted the three Society-owned journals as their official journals, whilst a fourth journal is co-owned with them.

The Society also has an agreement with John Wiley & Sons, whereby their journal *Clinical Endocrinology* is an official journal of the Society.

The Society is supported by a cross-section of industry, overseen by the Corporate Liaison Committee. The Society's multi-tiered corporate supporter scheme provides a forum for two-way dialogue between the Society and industry across issues including therapeutic development and regulation. The corporate supporter scheme is multi-tiered.

Much of our work takes place in conjunction with Patient Support Groups who represent patients with endocrine conditions. The Society actively works with 20 patient support groups who attend our events and contribute to guidance. Funding is made available to these groups via a grant scheme to support attendance at our events and specific patient projects.

#### *Volunteers*

The Society is largely run by members – scientists, clinicians and nurses who volunteer their time and expertise to carry out and continually develop Society activities. Approximately 100 members sit on committees, over 100 members and non-members currently serve on journal editorial boards, and many more assist with programme development meetings, as speakers and chairs, and with other activities. The Society is immensely grateful to all these volunteers for their tireless work.

### **Successes in 2019**

The Society's portfolio of activities is developed in line with five broad objectives:

1. Recruiting the next generation
2. Supporting career development at all stages
3. Setting the highest standards
4. Facilitating and creating knowledge exchange
5. Collaborating within and beyond the endocrinology community

### **Recruiting the next generation**

In 2019 the Society launched a new programme that aims to identify and nurture future leaders in endocrinology. The Leadership and Development Awards programme is a 3-year programme for selected early career individuals who have demonstrated commitment and leadership in the discipline. The benefits of the programme include structured networking opportunities with leaders in the endocrinology, tailored leadership training, opportunities to sit on Society committees, editorial boards and other panels and access to an Advisory Group who provide ad hoc mentoring services. This programme will run annually and recruit up to 8 individuals in each cohort.

Other achievements in 2019 included work with the early career group of Diabetes UK (YDEF) to organise the third National Endocrinology and Diabetes Taster Day. This event aims to showcase endocrinology and diabetes to inspire undifferentiated medical trainees and encourage them to choose E&D as their specialty.

In 2019 we also funded 12 summer studentships to allow undergraduates to complete a supervised laboratory research placement, giving them more exposure to endocrinology.

**SOCIETY FOR ENDOCRINOLOGY**  
**REPORT OF THE COUNCIL OF MANAGEMENT**

---

**About us (cont.)**

During the year we started to develop a new Society Award to recognise the outstanding teaching undertaken by many of our members. The intention of this award is also to share inspirational examples of best practice that enthuse unspecialised scientists and medics about endocrinology.

Over 2019 we also worked with the Association of British Clinical Diabetologists to put together a position statement recommending a minimum of 2 years protected specialty training time for Endocrinology & Diabetes trainees that we feel strongly will better equip future endocrinologists to tackle the clinical challenges they face. The statement has been acknowledged by the General Medical Council which represents an important step forward.

**Supporting career development at all stages**

The Society runs a programme of events and grants that aims to support the training and professional development of all our members at all career stages. Our portfolio of Prizes and Awards aims not only recognise and celebrate excellence, but also to inspire and share best practice.

Our events programme was particularly successful in 2019. Clinical Update, Endocrine Nurse Update and National Clinical Cases were all sold out and received excellent delegate feedback on the quality of the events.

The Society's annual conference, SfE BES, attracts around 1000 endocrinologists each year, and in 2019 the programme was refocused around our Endocrine Network themes, which empowered our subspecialty groups and ensured the content truly reflected the most cutting edge science across endocrinology. In addition we introduced new innovation and skills sessions, as well as further networking opportunities to support our members' career development. The revised programme helped attract 942 paid delegates, compared to 758 the previous year.

In 2019 £450k was made available in grants to fund research, travel to conferences, public engagement and patient support for our members' professional development. Within this, a new grant was introduced to support five endocrine nurses to undertake masters-level training in Adult Endocrine Nursing in conjunction with Oxford Brookes University.

|                                   | <b>Applications</b> | <b>Awarded</b> | <b>Value (£)</b> |
|-----------------------------------|---------------------|----------------|------------------|
| Conference grants                 | 219                 | 209            | 117,051          |
| SfE BES free places               | 53                  | 30             | 11,401           |
| Early career grants               | 58                  | 18             | 175,645          |
| Summer studentships               | 29                  | 12             | 25,965           |
| Patient support grants            | 7                   | 7              | 3,031            |
| Public engagement grants          | 5                   | 5              | 4,693            |
| Undergraduate achievement awards  | 20                  | 20             | 6,000            |
| Practical skills grants           | 4                   | 4              | 8,000            |
| Equipment grants                  | 10                  | 2              | 19,100           |
| Clinical department grants        | 6                   | 6              | 6,000            |
| Endocrine Networks Support Grants | 3                   | 3              | 7,249            |
| Themed Scientific Meeting Grants  | 4                   | 1              | 7,215            |
| Other                             | 6                   | 6              | 3,000            |
| <b>Total</b>                      | <b>424</b>          | <b>323</b>     | <b>394,350</b>   |



**About us (cont.)**

**Setting the highest standards**

The Society is uniquely placed to set clinical guidance on best practice within endocrinology. We achieve this by developing and publishing guidance on diagnosis and treatment of endocrine conditions. Alongside guidance documents, our programme of Interdepartmental Peer Review provides an external assessment of clinical governance and service delivery and aims to improve services for endocrine patients. By focusing on basic standards for endocrine care and service provision, the review facilitates the sharing of best practice with the ultimate aim of raising and harmonising standards of care across the UK.

In 2019 we published new guidance on inpatient management of cranial diabetes insipidus (CDI). These guidelines recommend treatment pathways for patients with known CDI admitted to hospital, to ensure the safe management of patients with CDI. Several guidance documents are in progress for publication in 2020.

During the year we published a joint position statement with the British Society of Echocardiography and the British Heart Valve Society: Echocardiography and monitoring patients receiving dopamine agonist therapy for hyperprolactinaemia. We also worked with the British Thyroid Association to issue a statement against new treatment recommendations for subclinical hypothyroidism.

During the year, we conducted peer reviews of endocrine centres located in Aberdeen, Inverness, Cumbria and Plymouth. Running parallel throughout 2019 was the NHS's improvement programme 'Get it Right First Time' (GIRFT), which assessed each centre across the country. The Society's Peer Review programme aims to build on this work throughout 2020, particularly focusing around the recommendations from GIRFT.

**Facilitating and creating knowledge exchange**

The Society's portfolio of journals and research projects, together with our events programme, provide effective platforms for gathering and disseminating new knowledge, from the fundamental molecular science of endocrinology through translation work to best clinical practice.

The Society's four owned journals and fifth endorsed journal continue to perform well and their quality is reflected in their impact factors, shown below.

| Journal                                   | 2015  | 2016  | 2017  | 2018  | 2019  |
|---|-------|-------|-------|-------|-------|
| <i>Journal of Endocrinology</i>           | 3.781 | 4.498 | 4.706 | 4.012 | 4.381 |
| <i>Journal of Molecular Endocrinology</i> | 3.081 | 2.947 | 3.577 | 3.297 | 3.744 |
| <i>Endocrine-Related Cancer</i>           | 4.805 | 4.472 | 5.267 | 5.331 | 4.774 |
| <i>Endocrine Connections</i>              |       |       | 2.541 | 3.041 | 2.474 |

The Society's five long-standing research projects continued throughout 2019 and all of these are now in their final stages: two long standing projects, the UK Acromegaly Register, Congenital Adrenal Hyperplasia Adult Study Executive (CaHASE) and three additional projects: Apoplexy audit, post-radiation Graves Managements (PRAGMA) and Transitional Care. The projects were funded by grants from the Clinical Endocrinology Trust (CET) or educational grants from pharmaceutical

### **About us (cont.)**

companies. The research projects continue to provide valuable data utilised in presentations at international meetings and published in peer-reviewed journals.

In addition, a new research study was set up in 2019: the Anti-thyroid drug study, which aims to identify those likely to have severe side effects caused by anti-thyroid drugs. This project is funded by the CET.

### **Collaborating within and beyond the endocrinology community**

The membership base of the Society continued to grow over the year with the total number of paid members at the end of the 2019 subscription year was 2740 compared to 2565 the previous year. A revised set of membership categories was implemented in the autumn of 2019 designed to be more inclusive to members and to allow the Society to better segment and understand its membership profile.

Following the categories project, further developments were made to the Society's membership database to enable us to record more of the roles that individuals hold within the Society, allowing us to look more closely at member engagement.

Endocrinology is a broad discipline. Our subspecialty group called Endocrine Networks enable the Society to understand the diverse challenges our discipline faces as well as the cutting edge research and practice within each area. The Networks act as a platform for collaboration between basic and clinical researchers, clinical endocrinologists and endocrine nurses, the Networks enable members to engage and find solutions to challenges within their specialist field of endocrinology. In 2019 we established a further Endocrine Network: The Endocrine Consequences of Living With and Beyond Cancer. Our eight Networks are listed below:

- Adrenal and Cardiovascular
- Bone and Calcium
- Endocrine Consequences of Living with and Beyond Cancer
- Endocrine Neoplasia Syndromes
- Metabolic and Obesity
- Neuroendocrinology
- Reproductive Endocrinology and Biology
- Thyroid

The Society is committed to helping people make better decisions about their health by engaging widely with non-specialists. We disseminate accurate up-to-date information about hormones to the public and empower our members with the tools, training and opportunities they need to be able to deliver effective public engagement. Our activities include press work, delivering hands-on activities at science and community festivals, running training sessions for members and managing online resources including a public-facing website *You and Your Hormones*.

*You and Your Hormones* receives up to 13,000 page views a day. In 2019 the Society created an editorial board and tier of 13 content reviewers for *You and Your Hormones*. This has not only strengthened the editorial control and direction, but provided more opportunities for members to contribute in a meaningful way.

In addition to promoting science published in our journals or presented at our events and providing expert comment to journalists we also actively tackled high profile yet misinformed stories in *The Times* and *The Guardian* which raised the Society's profile with these publications as a trustworthy source of expertise.

**About us (cont.)**

**Structure, governance and management**

The Society was established in 1939. It is a company limited by guarantee and was registered as a charity in the UK in 1961. Our beneficiaries are Society members, clinicians and researchers working on the endocrine system and related disciplines, patients, their support groups, students and the general public. Our governing documents are our Memorandum and Articles of Association, supplemented by our Bylaws.


*Council*

The Society is governed by a Council consisting of twelve trustees elected by the membership, supported by a number of committees. The trustees fulfil the dual roles of being charity trustees and company directors of the Society. Committee chairs attend Council in an ex-officio capacity together with the Chairman of Bioscientifica Limited, the Society's wholly-owned trading subsidiary, and an Early Career Endocrinologist representative. The ex-officio members and observers are not trustees or directors and are not entitled to vote.

Members of Council must be Full Members of the Society. Vacant positions are advertised to the membership for nomination by a Full Member. If there are more nominations than vacancies, the Full Members are balloted. The new Council members are announced at the AGM.

All new Council members are invited to attend an induction session covering governance, finance and the major areas of activity. Trustee update briefings on changes in legislation and regulations are provided annually.

The committee structure reporting into Council is as follows:



The Officers' sub-committee handles the day to day management issues between Council meetings and is comprised of the President, General Secretary, Treasurer, and Programme Secretary. They are elected specifically to these posts one year in advance of taking office, whereupon they shadow their role for a year. The Treasurer serves a term of office of five years, with the remaining roles completing a three-year term of office. All other Council members serve a four-year term.

Committee chairs are appointed as follows:

**Committee**

Programme Committee  
 Finance Committee  
 Nominations Committee  
 Publications Committee

All other committees

**Chair**

Programme Secretary  
 Treasurer  
 President  
 Normally the General Secretary, otherwise a trustee of the Society nominated by Council  
 Appointed by Council

**About us (cont.)**

Committees have a degree of autonomy as regards their composition and methods of election/appointment, but always subject to Council's approval. The structure and remit of committees are reviewed by Council periodically.

Council also appoints the Editors-in-Chief of the three Society-owned journals and that of the Society's magazine, *The Endocrinologist*. The Editor-in-Chief of the journal *Endocrine Connections* is appointed by Council in conjunction with the Executive Committee of the co-owners, the European Society of Endocrinology.

All members of Council and its committees give their time voluntarily to the Society.

*Trustees*

In shaping our objectives and planning our activities the Trustees have considered the Charity Commission's guidance on public benefit including *Public Benefit: Running a charity (PB2)*. The Trustees are satisfied that the activities of the Society provide public benefit through supporting the advancement of the understanding of hormones, improving clinical practice, publishing high quality research in our journals, organising meetings, conferences and networking events, and informing and engaging the public in the importance of endocrinology.

*Remuneration of key management personnel*

Working in close collaboration with Council, our Executive Team, led by the Chief Executive, manages the implementation and operational delivery of the Society's strategic objectives and ensures that the Society is governed and managed effectively.

The Society's staff report to the General Secretary through the Chief Executive. Remuneration Group oversees staff salaries and benefits and sets the remuneration of key management personnel which are benchmarked against similar organisations and appropriate ONS inflation and wage increase measures. The Remuneration Group comprises representatives of the Officers, the Chair of Bioscientifica Limited, the Chief Executive and is attended by the audit lead partner, as independent advisor.

**Bioscientifica Limited**

The Society's activities are made possible by funding from our wholly owned trading subsidiary, Bioscientifica, which publishes our journals, manages our events and provides membership services. Bioscientifica exists to support biomedicine. Through its expertise in publishing, professional conference organisation and association management we strengthen biomedical communities to advance science and health.

Established in 1996, Bioscientifica Limited returns its surplus profits back to the Society for Endocrinology via Gift Aid and also provides funding for the Bioscientifica Trust.

**Office accommodation**

The Society acquired the freehold of its current office building, Starling House, situated at 1600 Bristol Parkway North on 1 March 2018. Its former office accommodation at 22 Apex Court on the Almondsbury Business Park in North Bristol was divested on 31 October 2019.

## Investment policy and performance

The investment portfolio is managed by Brewin Dolphin Limited under a discretionary investment management arrangement. There are no restrictions on the charity's power to invest. The investment strategy is set by the trustees and takes into account income requirements, the risk profile and the investment manager's view of the market prospects.

The policy is to maximise total return through a diversified portfolio whilst providing a level of income advised by the trustees from time to time. There is also an Ethical Policy excluding investment in companies that derive more than 10% of their turnover from the tobacco industry or anything clearly injurious to health.

The investment brokers prepare portfolio valuation reports on a monthly basis in addition to more detailed quarterly reports for Trustees. Additional reports are prepared for each Finance Committee meeting including comparison with the appropriate benchmarks. The Finance Committee meets three times a year and the investment manager normally attends at least one meeting.

The value of listed investments increased to £3,742k from £3,310k during the year, largely as a result of increases in the value of equities held in the investment fund. The portfolio experienced unrealised gains on investments held at the year-end of £384k. The total investment income from the portfolio for the year was £108k. Cash reserves for the Society and Bioscientifica Limited together stood at £2,209k at the year-end. This includes cash held on behalf of third parties.

The investments of the Main Fund are shown in note 14 to the accounts.

## Financial review

### *Financial overview*

In line with the Society's plans to reduce surplus reserves, a deficit budget was set for the year. The main source of funds for the Society derives from its journals and Gift Aid from Bioscientifica Limited. The Society publications continue to perform strongly financially, despite the pressures on the industry, on the back of excellent editorial performance and consistently account for 65-70% of the Society's charitable income (2019 67%). The Gift Aid generated by Bioscientifica Limited accounted for 38% (2018 25%) of income from trading activities.

Event income from delegates and sponsors was 64% of total income (2018 58%) and generated a gross surplus, before overheads, of £73k (2018 deficit £48k).

Other membership services account for £1,381k of charitable expenditure (2018 £1,111k) and cover the management of the membership, networks, public and media activities, professional and career, prizes and awards and nurse activities. Grants continue to be a major part of the support to the membership with £396k awarded during the year (2018 £392k).

### *Reserves policy*

To date, funding has been derived mainly from surpluses from publishing and event management activities through the trading company, and income from membership and its own investments.

The reserves policy assumes that, in the event of a severe financial crisis, the Society would require sufficient funds to run on a going concern basis for a two-year period, during which time the Society's position would be evaluated. Existing projects would be financed for up to two years at a level based on priorities agreed by Council. In the event that no viable alternatives for financing could be identified, the Society would be wound up. It has been assumed that the sale of the office premises would provide sufficient funds to cover any associated costs.

The Trustees reviewed the policy in December 2017 and confirmed that the reserves figure should remain unchanged at £3.44M. The figure for readily available reserves at 31 December 2019 was £4.14M (31 December 2018 - £3.76M), exceeding the reserve requirement by £0.7M.

**Financial review (cont.)**

*COVID-19*

Recognising the increasing impact of COVID-19 globally, and more specifically in the UK, the Trustees held an extraordinary meeting by video conference on 8 April 2020 to discuss the impact of the pandemic on the Society's future plans. It was agreed to continue with activities as close to 'business as usual' as possible – including continued planned expenditure on grants – while realising cost savings that do not impact on long-term goals. It was acknowledged that the Society may need to utilise its reserves to sustain activities through the pandemic and beyond. The Trustees will discuss revised year-end and cash-flow forecasts at each meeting until the full financial impact of the crisis is known, and will make any adjustments to future plans considered appropriate according to the circumstances.

*Bioscientifica Limited*

Bioscientifica Limited's profit before Gift Aid and taxation of £1,281k (£49k lower than budget) represents a satisfactory performance in the light of the challenges faced by Bioscientifica in each of its trading divisions. The company generates funds for the Society by providing products and services to third parties in areas where the Society's staff have expertise. This also allows cost-effective sharing of overheads. The main areas of activity are publishing, event management and association management with the majority of clients being scientific and medical societies, the pharmaceutical industry and international universities and research institutions. A summary of financial results is shown in note 3 to the accounts, and Bioscientifica will remit £1,272k to the Society through Gift Aid. The Bioscientifica Limited business plan forms the basis of current and future activity across the company's main divisions and identifies targets for product development and growth. Business strategy is predicated on growth and development in all three business units and on the continuance of major client relationships.

**Risk review**

The Society maintains a risk register that covers main business risks across the organisation and is reviewed regularly by the Council of Management. A separate register is held for Bioscientifica Limited to manage specific risks for the company which is overseen by the company's Board of Directors. Key operational risks are held across the Group and thus appear on both registers.

During the year, the Society carried no risks deemed to be in a 'red' status, i.e. having a combination of high impact and high likelihood. The Society's register identified 15 risks, 10 of which were deemed to be in 'amber' status where the risk gives cause for concern but is under control or acceptable. Of these amber risks the most significant were:

*Problems with Finance systems and processes impacting on reporting, planning, and service delivery*

- Improvements to systems, processes and controls made throughout 2018, and incrementally during the course of 2019 will take time to fully work through the organisation but the benefits of more robust and timely financial reporting, improved budgeting and forecasting and better strategic financial planning and support were seen in 2019.

*Business systems not delivered to schedule and impacting business as usual as well as strategic activity*

- We did not have any major new system delivery or upgrades planned in 2019 but we feel that we have failed to realise the full benefits of the member management software implemented in 2016. We are therefore reviewing the business systems in this area in order to improve utility and efficiency.

**Risk review (cont.)**

*Loss of key staff*

- As a small organisation we rely very heavily on key staff. The senior management team was reorganised in the summer of 2017 in part to reduce this risk, to build in a greater level of succession planning and to ensure that expertise and knowledge is more widely shared. The risks are further mitigated through robust business continuity plans with reviews of organisational structure and organisation of workloads to reduce the impact of the loss of key staff. Retention is improved through continuous work on staff engagement and the Society once again received recognition in the Sunday Times list of the best 100 not-for-profit companies to work for.

*Significant loss of pharmaceutical sponsorship*

- The requirements of pharmaceutical companies are changing rapidly in light of developing regulation and challenges in new product development. This is putting pressure on the support they offer to learned societies like us and consequently on the financial support we receive from them. We have developed new offerings in partnership with our corporate supporters and also formed a Corporate Relations Committee to oversee our relationship with industry.

*Unexpected reduction of Gift Aid by >£200k from Bioscientifica*

- This risk was primarily driven by the continued uncertainty over Brexit throughout most of 2019, and the potential impact that this could have on partnerships with European organisations and the exchange rate impact on overseas revenues from our journal publishing business. In fact, Bioscientifica performed very well and very nearly achieved its budgeted profit for the year.

During the first 3 months of 2020 the Society risk register has been modified to reflect the additional risks associated with Covid-19. Several already identified risk factors are now assessed to have either a higher level of impact and/or higher likelihood of occurrence than previously. The main changes have been as follows:

*Loss of essential IT infrastructure*

- The requirement that all non-essential workers should work from home wherever possible has increased the reliance of the organisation on the availability of remote IT services. In response, additional key software licences have been procured, and uniform, cloud-based meeting software has been installed on all staff laptops. The resilience of the Society VPN and cyber-security measures have also been tested and assured.

*Realisation of catastrophic losses on financial investments*

- The heightened volatility in world financial markets in the first quarter of 2020 has caused significant variation, and downward pressure, in the market value of the Society investment portfolio over the period. Whilst the revised cash forecast for 2020 does not suggest a need to realise a material proportion of current investments, any longer-term catastrophic fall in world stock markets could cause the Society to reconsider its longer term strategic ambitions. As noted above, the Society has appointed Brewin Dolphin to manage its investments, and will follow the advice provided by Brewin Dolphin as to appropriate investment strategies as world financial markets react to the Covid-19 situation. At 31 March 2020 there remained over £1M of headroom on the loan covenant relating to the market value of the Society investment portfolio.

**Statement of Trustees' responsibilities**

The Trustees (who are also Directors of the Society for the purposes of Company Law) are responsible for preparing the Report of the directors (including the Strategic Report) and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice) which give a true and fair view of the state of affairs of the charitable company and the group and of the incoming resources and application of resources, including the income and expenditure, of the charitable company and group for that period.

## Strategy

In preparing these financial statements, the Trustees are required to:

- Select suitable accounting policies and then apply them consistently
- Observe the methods and principles of the Charities Statement of Recommended Practice
- Make judgements and estimates that are reasonable and prudent
- State whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements, and
- Prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in operation

The Trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

In so far as the Trustees are aware:

- There is no relevant audit information of which the Society's auditor is unaware, and
- The Trustees have taken all the steps that they ought to have taken as Trustees to make themselves aware of any relevant audit information and to establish that the auditor is aware of that information

The Trustees are responsible for keeping proper accounting records that disclose, with reasonable accuracy at any time, the financial position of the charitable company and group and to enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and group and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

## Funds held as custodian trustee on behalf of others

Within Bioscientifica Limited are held funds of £339k belonging to clients of the company. These funds relate to contracts which involve Bioscientifica collecting and holding income on behalf of clients that is usually utilised to pay client expenditure before remitting the surplus to the client.

Registered Office

Starling House  
1600 Bristol Parkway North  
Bristol BS34 8YU

In approving the Trustees' Report, the Trustees are also approving the Strategic Report included here in their capacity as Company Directors.

On behalf of the Council



E Davies

General Secretary

Dated : 23 July 2020



## **Audit Report**

### **Opinion**

We have audited the financial statements of Society for Endocrinology for the year ended 31 December 2019 which comprise the Consolidated Statement of Financial Activities, the Consolidated and Parent Charitable Company Balance Sheets, the Consolidated Cash Flow Statement and the related notes. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion, the financial statements:

- give a true and fair view of the state of the charitable company and group's affairs as at 31 December 2019 and of the charitable company and group's net movement in funds, including the income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

### **Basis for opinion**

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the group in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

### **Responsibilities of trustees for the financial statements**

As explained more fully in the trustees' responsibilities statement on pages 14-15, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

## **Audit Report (cont.)**

### **Auditor's responsibilities for the audit of the financial statements**

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at: [www.frc.org.uk/auditorsresponsibilities](http://www.frc.org.uk/auditorsresponsibilities). This description forms part of our auditor's report.

### **Conclusions relating to going concern**

We have nothing to report in respect of the following matters in relation to which the ISAs (UK) require us to report to you where:

- the trustees' use of the going concern basis of accounting in the preparation of the financial statements is not appropriate; or the trustees have not disclosed in the financial statements any identified material uncertainties that may cast significant doubt about the charitable company's ability to continue to adopt the going concern basis of accounting for a period of at least twelve months from the date when the financial statements are authorised for issue.

### **Other information**

The trustees are responsible for the other information. The other information comprises the information included in the Trustees' Report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

### **Opinions on other matters prescribed by the Companies Act 2006**

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the Trustees' Report (which incorporates the strategic report and the directors' report) for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the Trustees' Report (which incorporates the strategic report and the directors' report) has been prepared in accordance with applicable legal requirements.

**Audit Report (cont.)**

**Matters on which we are required to report by exception**

In the light of the knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the Trustees' Report (which incorporates the strategic report and the directors' report).

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:

- adequate accounting records have not been kept by the charitable company; or
- the charitable company financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit

**Use of audit report**

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charitable company's members those matters we are required to state to them in an Auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company's members as a body, for our audit work, for this report, or for the opinions we have formed.



**Kathryn Burton**  
**Senior Statutory Auditor**  
for and on behalf of Haysmacintyre LLP, Statutory Auditors

**10 Queen Street Place**  
**London**  
**EC4R 1AG**

**Date:** 28 July 2020

haysmacintyre is eligible to act as an auditor in terms of Section 1212 of the Companies Act 2006.

**SOCIETY FOR ENDOCRINOLOGY**

CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES (INCORPORATING THE INCOME AND EXPENDITURE ACCOUNT) FOR THE YEAR ENDED 31 DECEMBER 2019

|                                    |      | Year ended 31 December 2019 |                          | Year ended 31 December 2018 |                     |
|------------------------------------|------|-----------------------------|--------------------------|-----------------------------|---------------------|
|                                    | Note | Unrestricted Funds<br>£000  | Restricted Funds<br>£000 | Total Funds<br>£000         | Total Funds<br>£000 |
| <b>Income and endowments from:</b> |      |                             |                          |                             |                     |
| Charitable activities              | 4    | 2,775                       | -                        | 2,775                       | 2,610               |
| Other trading activities           | 5    | 3,308                       | -                        | 3,308                       | 3,622               |
| Investments                        |      | 103                         | 10                       | 113                         | 110                 |
| Other                              | 6    | 336                         | -                        | 336                         | 143                 |
| <b>Total</b>                       |      | <b>6,522</b>                | <b>10</b>                | <b>6,532</b>                | <b>6,485</b>        |
| <b>Expenditure on:</b>             |      |                             |                          |                             |                     |
| Raising funds                      | 7    | 3,532                       | -                        | 3,532                       | 4,077               |
| Charitable activities              | 8    | 2,746                       | 5                        | 2,751                       | 2,450               |
| Other                              |      | 17                          | 2                        | 19                          | 20                  |
| <b>Total</b>                       |      | <b>6,295</b>                | <b>7</b>                 | <b>6,302</b>                | <b>6,547</b>        |
| Net (losses)/gains on investments  |      | 357                         | 28                       | 385                         | (246)               |
| <b>Net (expenditure)/income</b>    |      | <b>584</b>                  | <b>31</b>                | <b>615</b>                  | <b>(308)</b>        |
| <b>Transfers between funds</b>     |      | <b>18</b>                   | <b>(18)</b>              | <b>-</b>                    | <b>-</b>            |
| <b>Net Movement in funds</b>       |      | <b>602</b>                  | <b>13</b>                | <b>615</b>                  | <b>(308)</b>        |
| <b>Reconciliation of funds:</b>    |      |                             |                          |                             |                     |
| Total funds brought forward        |      | 4,802                       | 357                      | 5,159                       | 5,467               |
| <b>Total funds carried forward</b> |      | <b>5,404</b>                | <b>370</b>               | <b>5,774</b>                | <b>5,159</b>        |

The surplus for the Charitable Company for the year totalled £614,566 (2018 deficit: £308,124).

All of the above amounts relate to continuing activities.

The notes on pages 22 to 41 form part of these financial statements

**SOCIETY FOR ENDOCRINOLOGY**

## GROUP AND COMPANY BALANCE SHEETS AT 31 DECEMBER 2019

|  | Note | Group<br>£000 | Company<br>£000 | Group<br>£000 | Company<br>£000 |
|--|------|---------------|-----------------|---------------|-----------------|
| <b>Fixed Assets:</b>                           |      |               |                 |               |                 |
| Intangible assets                              | 12   | 54            | 54              | 52            | 52              |
| Tangible assets                                | 13   | 1,962         | 1,962           | 1,980         | 1,980           |
| Investments                                    | 14   | 3,814         | 3,814           | 3,385         | 3,385           |
| Investment in Bioscientifica Limited           | 3    | -             | 1               | -             | 1               |
| <b>Total fixed assets</b>                      |      | <b>5,830</b>  | <b>5,831</b>    | <b>5,417</b>  | <b>5,418</b>    |
| <b>Current Assets</b>                          |      |               |                 |               |                 |
| Assets held for sale                           |      | -             | -               | 411           | 411             |
| Debtors  | 15   | 1,924         | 216             | 2,847         | 778             |
| Cash at bank and in hand                       | 16   | 2,209         | 1,003           | 1,669         | 333             |
| <b>Total current assets</b>                    |      | <b>4,133</b>  | <b>1,219</b>    | <b>4,927</b>  | <b>1,522</b>    |
| <b>Liabilities:</b>                            |      |               |                 |               |                 |
| Creditors: Amounts falling due within one year | 17   | 3,377         | 695             | 4,155         | 800             |
| Net current assets                             |      | 756           | 524             | 772           | 722             |
| Total assets less current liabilities          |      | 6,586         | 6,355           | 6,189         | 6,140           |
| Long term loans                                |      | 812           | 812             | 1,030         | 1,030           |
| <b>Net assets</b>                              |      | <b>5,774</b>  | <b>5,543</b>    | <b>5,159</b>  | <b>5,110</b>    |
| <b>The funds of the charity:</b>               |      |               |                 |               |                 |
| Restricted income funds                        | 18   | 370           | 370             | 357           | 357             |
| Unrestricted funds                             | 19   | 5,404         | 5,173           | 4,802         | 4,753           |
| <b>Total charity funds</b>                     |      | <b>5,774</b>  | <b>5,543</b>    | <b>5,159</b>  | <b>5,110</b>    |


These financial statements were approved by the directors and authorised for issue on 23 July 2020 and are signed on their behalf by:

E DAVIES



GENERAL SECRETARY

B MCGOWAN



TREASURER

Company registration number: 349408

The notes on pages 22 to 39 form part of these financial statements

**SOCIETY FOR ENDOCRINOLOGY**

## CONSOLIDATED CASH FLOW STATEMENT FOR THE YEAR ENDED 31 DECEMBER 2019

|   | Note     | 2019<br>£000 | 2018<br>£000   |
|---|----------|--------------|----------------|
| <b>Cash flows from operating activities:</b>  |          |              |                |
| <b>Net cash provided by / (used in) operating activities</b>                                | <b>a</b> | <u>172</u>   | <u>(485)</u>   |
| <b>Cash flows from investing activities:</b>  |          |              |                |
| Dividends and interest  |          | 113          | 110            |
| Purchase of property, plant and equipment   |          | (92)         | (1,973)        |
| Proceeds from sale of investments   |          | 831          | 1,045          |
| Purchase of investments   |          | (879)        | (1,959)        |
| Movement in cash awaiting investment  |          | 2            | 1,737          |
| <b>Net cash provided by investing activities</b>  |          | <u>(25)</u>  | <u>(1,040)</u> |
| <b>Sale of property asset held for resale</b>   |          | <u>612</u>   | <u>-</u>       |
| <b>Movement in Long Term Loans</b>  |          | <u>(219)</u> | <u>1,030</u>   |
| Change in cash and cash equivalents in the reporting period                                 |          | 540          | (495)          |
| Cash and cash equivalents at the beginning of the reporting period                          | <b>b</b> | <u>1,669</u> | <u>2,164</u>   |
| <b>Cash and cash equivalents at the end of the reporting period</b>                         | <b>b</b> | <u>2,209</u> | <u>1,669</u>   |
| <b>a) Reconciliation of net income to net cash flow from operating activities</b>           |          |              |                |
| <b>Net (expenditure)/income for the year (as per the statement of financial activities)</b> |          | 616          | (308)          |
| <b>Adjustments for:</b>   |          |              |                |
| Depreciation and amortisation charges   |          | 108          | 114            |
| Gains on investments  |          | (384)        | 246            |
| Dividends and interest from investments   |          | (112)        | (110)          |
| Profit on sale of property held for resale  |          | (202)        | -              |
| Decrease in debtors   |          | 924          | 48             |
| Decrease in creditors   |          | (778)        | (475)          |
| <b>Net cash provided by operating activities</b>  |          | <u>172</u>   | <u>(485)</u>   |
| <b>b) Analysis of cash and cash equivalents</b>   |          |              |                |
| Cash in hand  |          | 1,027        | 1,180          |
| Notice deposits (less than 3 months)  |          | 1,182        | 489            |
| <b>Total cash and cash equivalents</b>  |          | <u>2,209</u> | <u>1,669</u>   |

**1) Accounting policies****a) General information**

The Society for Endocrinology (“the Society”) is a charitable company limited by guarantee incorporated in England and Wales (co. number 349408) and registered with the Charity Commission (Charity Registration no. 266813). The Society’s registered office address is Starling House, 1600 Parkway North, Bristol BS34 8YU.

**b) Basis of preparation**

The financial statements have been prepared under the historical cost convention, as modified by the revaluation of listed investments, and in accordance the Statement of Recommended Practice for Charities (SORP 2015), with applicable accounting standards (FRS 102) and the Companies Act 2006.

**c) Basis of consolidation**

The statement of financial activities (SOFA) and balance sheet consolidate the financial statements of the charity and its wholly owned subsidiary undertaking, Bioscientifica Limited. The results of the subsidiary are consolidated on a line-by-line basis.

The charity has taken exemption from presenting a separate statement of financial activities under section 408 of the Companies Act 2006.

**d) Going concern**

In assessing the ability of the Society and Group to continue as a going concern, the Trustees have considered the Society and Group liquidity position, and reviewed cash flow forecasts for the foreseeable future.

For this reason, the Trustees continue to adopt the going concern basis in preparing the accounts.

**e) Income and endowments**

Income includes:

- i)** Donations received in the year
- ii)** Grants and royalties which are accounted for on a received basis
- iii)** Investment income received during the period includes dividends and bank interest, on an accruals basis
- iv)** Subscriptions which are accounted for on the accruals basis and deferred if paid in advance
- v)** Sponsorship, event income and other publication income are recognised when delivered

**f) Expenditure**

Expenditure is included when incurred and is matched with the relevant income stream.

Costs of raising funds include all costs of the activities of the trading subsidiary (excluding the Society-owned publications), investment managers’ fees and any costs associated with generating voluntary income.

Charitable activities include all costs that relate to the generation of income to further the charity’s objects.

Support costs shown in note 9 represent the indirect costs incurred in providing support for all activities of the charity and governance costs. These have been allocated on the basis of the direct costs of the relevant activity.

Governance costs include Council and committee expenses and statutory and constitutional costs.

**g) Intangible fixed assets and amortisation**

Intangible assets represent computer software and are stated at cost less amortisation. Such assets are capitalised where the total cost exceeds £200. Software costs are amortised over 5 years, representing the expected useful life.

**h) Tangible fixed assets and depreciation**

Tangible fixed assets are stated at cost (or deemed cost) less accumulated depreciation and accumulated impairment losses. Fixed assets are capitalised where the total cost exceeds £200.

Depreciation is provided on all tangible assets, other than freehold land, to write off the cost, less estimated residual value of each asset over its expected useful life on a straight-line basis. The estimated useful lives are as follows:

|                       |                 |
|-----------------------|-----------------|
| Buildings             | : 50 years      |
| Fixtures and fittings | : 5 to 10 years |
| Office equipment      | : 3 to 5 years  |

**i) Listed investments**

Listed investments are stated at market value at the period-end.

Gains and losses on disposal and revaluation of investments are charged or credited to the SOFA.

**j) Financial instruments – assets and liabilities**

*Cash and cash equivalents*

Cash and cash equivalents includes cash in hand, deposits held at banks, other short-term highly liquid investments with original maturities of three months or less and bank overdrafts. Bank overdrafts, when applicable, are shown within current liabilities.

*Debtors and creditors*

Debtors and creditors with no stated interest rates are recorded at transaction price. Any losses arising from impairment are recognised in the Statement of Financial Activities.

**k) Pensions**

The Society contributes to the personal pensions arrangements of certain staff. The assets are held separately from those of the Society in independently administered funds. The contributions are charged to the Statement of Financial Activities on a payments basis. The contributions paid are shown in note 11.

**l) Foreign currencies**

Transactions in foreign currencies are translated at rates prevailing at the date of the transaction. Bank balances denominated in foreign currencies are translated at the rate of exchange prevailing at the year-end.

**m) Client accounts**

The accounts held separately within debtors and creditors represent separate funds in respect of clients for whom the Society's subsidiary acts as an agent.



**n) Fund accounting**

The funds held by the Society are categorised as:

*Unrestricted Main Fund* – funds which can be used in accordance with the charitable objects of the Society at the discretion of the trustees

*Designated funds* - funds which have been put aside at the discretion of the trustees as explained in Note 19 to the accounts.

*Restricted funds* – funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the Society for particular purposes as explained in Note 18 to the accounts.

**o) Taxation**

The Society is exempt from income tax and corporation tax on income and gains derived from its charitable activities as these activities fall within various exemptions available to registered charities.

**p) Judgements in applying accounting policies and key sources of estimation uncertainty**

In the application of the society's accounting policies, the trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

The Trustees do not consider there to be any key areas of judgements estimation in the application of the Society's accounting policies.

**2) Income and endowments**

An analysis of Group income and endowments by geographical location is given below:

|                   | Year to<br>31/12/19 | Year to<br>31/12/18 |
|-------------------|---------------------|---------------------|
|                   | %                   | %                   |
| United Kingdom    | 27                  | 25                  |
| Europe            | 39                  | 46                  |
| North America     | 11                  | 12                  |
| Rest of the World | 23                  | 17                  |
|                   | <hr/> 100           | <hr/> 100           |

## **SOCIETY FOR ENDOCRINOLOGY**

NOTES TO THE ACCOUNTS FOR THE YEAR ENDED 31 DECEMBER 2019 (cont.)

### **3) Net income from trading activities of subsidiary**

The Society owns 1000 ordinary shares of £1 each at a total value of £1,000, representing the whole of the issued share capital of Bioscientifica Limited, a company incorporated in the United Kingdom. Bioscientifica Limited carries out journal and book publishing projects as well as providing conference and other series to the scientific community. A summary of the trading results is set out below.

| <b>Summary profit and loss account</b> | <b>Year to<br/>31/12/19</b> | <b>Year to<br/>31/12/18</b> |
|--|-----------------------------|-----------------------------|
|  | <b>£000</b>                 | <b>£000</b>                 |
| Turnover                               | 5,379                       | 5,586                       |
| Cost of sales                          | 2,944                       | 2,891                       |
| Gross profit                           | 2,435                       | 2,694                       |
| Administration                         | 1,195                       | 1,817                       |
| Operating profit                       | 1,240                       | 877                         |
| Interest receivable and similar income | 41                          | 52                          |
| Profit on ordinary activities          | 1,281                       | 929                         |
| Gift Aid                               | (1,098)                     | (929)                       |
| Profit before taxation                 | 183                         | -                           |
| Taxation                               | -                           | -                           |
| Retained in subsidiary                 | 183                         | -                           |

| <b>Total assets and liabilities of<br/>the subsidiary were:</b> | <b>Year to<br/>31/12/19</b> | <b>Year to<br/>31/12/18</b> |
|---|-----------------------------|-----------------------------|
|   | <b>£000</b>                 | <b>£000</b>                 |
| Fixed assets  | -                           | -                           |
| Current assets  | 2,914                       | 3,986                       |
| Creditors: amounts falling due<br>within one year               | 2,681                       | 3,936                       |
| Total net assets  | 233                         | 50                          |
| Aggregate share capital and<br>reserves                         | 233                         | 50                          |

The gift aid for the year of £1,098k was distributed in total to the Society for Endocrinology during 2019. The remainder will be paid across during 2020.

## **SOCIETY FOR ENDOCRINOLOGY**

NOTES TO THE ACCOUNTS FOR THE YEAR ENDED 31 DECEMBER 2019 (cont.)

### **4) Income from charitable activities**

|   | <b>Unrestricted funds</b> | <b>Restricted funds</b> | <b>Year to 31/12/19</b> | <b>Year to 31/12/18</b> |
|---|---------------------------|-------------------------|-------------------------|-------------------------|
|   | <b>£000</b>               | <b>£000</b>             | <b>£000</b>             | <b>£000</b>             |
| Publications  | 1,859                     | -                       | 1,859                   | 1,844                   |
| Society events and conferences (see below)          | 703                       | -                       | 703                     | 577                     |
| Other membership services (including subscriptions) | 193                       | -                       | 193                     | 170                     |
| Grants received                                     | 20                        | -                       | 20                      | 19                      |
|   | <b>2,775</b>              | <b>-</b>                | <b>2,775</b>            | <b>2,610</b>            |

No restricted fund income was received in 2019 or 2018.

Income from Society events and conferences includes:

|                                      | <b>Year to 31/12/19</b> | <b>Year to 31/12/18</b> |
|--------------------------------------|-------------------------|-------------------------|
|                                      | <b>£000</b>             | <b>£000</b>             |
| The Society annual meeting           | 520                     | 420                     |
| Training and other registration fees | 183                     | 157                     |
|                                      | <b>703</b>              | <b>577</b>              |

### **5) Income from other trading activities**

|  | <b>Unrestricted funds</b> | <b>Restricted funds</b> | <b>Year to 31/12/19</b> | <b>Year to 31/12/18</b> |
|--|---------------------------|-------------------------|-------------------------|-------------------------|
|  | <b>£000</b>               | <b>£000</b>             | <b>£000</b>             | <b>£000</b>             |
| Trading income from subsidiary company | 3,308                     | -                       | 3,308                   | 3,613                   |
| Sponsorship and exhibitions            | -                         | -                       | -                       | 9                       |
|  | <b>3,308</b>              | <b>-</b>                | <b>3,308</b>            | <b>3,622</b>            |

No restricted fund income was received in 2019 or 2018.

### **6) Other income**

|                                | <b>Unrestricted funds</b> | <b>Restricted funds</b> | <b>Year to 31/12/19</b> | <b>Year to 31/12/18</b> |
|--------------------------------|---------------------------|-------------------------|-------------------------|-------------------------|
|                                | <b>£000</b>               | <b>£000</b>             | <b>£000</b>             | <b>£000</b>             |
| Royalties received             | 149                       | -                       | 149                     | 143                     |
| Profit on sale of fixed assets | 187                       | -                       | 187                     | -                       |
|                                | <b>336</b>                | <b>-</b>                | <b>336</b>              | <b>143</b>              |

No other income was earned in respect of restricted funds in 2019 or 2018

**SOCIETY FOR ENDOCRINOLOGY**

NOTES TO THE ACCOUNTS FOR THE YEAR ENDED 31 DECEMBER 2019 (cont.)

**7) Expenditure on raising funds**

|                                     | <b>Unrestricted<br/>funds</b> | <b>Restricted<br/>funds</b> | <b>Year to<br/>31/12/19</b> | <b>Year to<br/>31/12/18</b> |
|-------------------------------------|-------------------------------|-----------------------------|-----------------------------|-----------------------------|
|                                     | <b>£000</b>                   | <b>£000</b>                 | <b>£000</b>                 | <b>£000</b>                 |
| Trading costs of subsidiary company | 3,532                         | -                           | 3,532                       | 4,077                       |

No costs were incurred in respect of restricted funds in 2019 or 2018

# SOCIETY FOR ENDOCRINOLOGY

NOTES TO THE ACCOUNTS FOR THE YEAR ENDED 31 DECEMBER 2019 (cont.)

## 8) Expenditure on charitable activities

|  | Direct costs | Grants paid | Support costs<br>(note 9) | Year to<br>31/12/19 | Year to<br>31/12/18 |
|--|--------------|-------------|---------------------------|---------------------|---------------------|
|  | £000         | £000        | £000                      | £000                | £000                |
| Publications   | 607          | -           | -                         | 607                 | 641                 |
| Society events and conferences                           | 400          | -           | 358                       | 758                 | 674                 |
| Other membership services (including subscriptions paid) | 509          | 418         | 454                       | 1,381               | 1,111               |
| Designated Strategy Fund                                 | -            | -           | -                         | -                   | -                   |
| Society research projects                                | 5            | -           | -                         | 5                   | 24                  |
|  | <b>1,521</b> | <b>418</b>  | <b>812</b>                | <b>2,751</b>        | <b>2,450</b>        |

| 2018   | Direct costs | Grants paid | Support costs<br>(note 9) | Year to<br>31/12/18 | Year to<br>31/12/17 |
|--|--------------|-------------|---------------------------|---------------------|---------------------|
|  | £000         | £000        | £000                      | £000                | £000                |
| Publications   | 641          | -           | -                         | 641                 | 620                 |
| Society events and conferences                           | 471          | -           | 203                       | 674                 | 649                 |
| Other membership services (including subscriptions paid) | 491          | 408         | 212                       | 1,111               | 1,092               |
| Designated Strategy Fund                                 | -            | -           | -                         | -                   | 3                   |
| Society research projects                                | 24           | -           | -                         | 24                  | 30                  |
|  | <b>1,627</b> | <b>408</b>  | <b>415</b>                | <b>2,450</b>        | <b>2,394</b>        |

Subscriptions paid by the Group include the following:

|   | Year to<br>31/12/19 | Year to<br>31/12/18 |
|---|---------------------|---------------------|
|   | £                   | £                   |
| International Society of Endocrinology                            | 5,756               | 5,352               |
| Understanding Animal Research                                     | 584                 | 572                 |
| Association of Medical Research Charities                         | 1,430               | 1,240               |
| Science Media Centre  | 2,000               | 2,000               |
| Meltwater Subscription  | 3,795               | 3,300               |
| STM Membership  | -                   | 3,095               |
| Web of Science  | 10,188              | 6,922               |
| ABPCO   | 2,094               | -                   |
| IAPCO   | 2,405               | 2,386               |
| (International Association of Professional Conference Organisers) |                     |                     |
|   | <b>28,252</b>       | <b>24,867</b>       |

**SOCIETY FOR ENDOCRINOLOGY**

NOTES TO THE ACCOUNTS FOR THE YEAR ENDED 31 DECEMBER 2019 (cont.)

**8) Expenditure on charitable activities (cont.)**

| Grants paid are made up as follows:                                 | Grants paid |            | Staff and other costs | Year to 31/12/19 | Year to 31/12/18 |
|---|-------------|------------|-----------------------|------------------|------------------|
|   | No          | £000       | £000                  | £000             | £000             |
| <i>Grants payable to individuals</i>                                |             |            |                       |                  |                  |
| Travel grants and grants for attendance at meetings and conferences | 239         | 128        | 3                     | 131              | 107              |
| Summer studentships   | 12          | 26         | 3                     | 29               | 35               |
| Early career grants   | 18          | 176        | 4                     | 180              | 181              |
| <b>Total grants payable to individuals</b>                          | <b>269</b>  | <b>330</b> | <b>10</b>             | <b>340</b>       | <b>323</b>       |
| <i>Grants paid to institutions:</i>                                 |             |            |                       |                  |                  |
| Patient support grants  | 7           | 3          | -                     | 3                | 21               |
| Public engagement grants  | 5           | 5          | -                     | 5                | 1                |
| Undergraduate achievement award                                     | 20          | 6          | -                     | 6                | 3                |
| Regional clinical cases grants                                      |             | -          | 2                     | 2                | 2                |
| Other grants  | 22          | 52         | 10                    | 62               | 58               |
| <b>Total grants paid to institutions:</b>                           | <b>54</b>   | <b>66</b>  | <b>12</b>             | <b>78</b>        | <b>85</b>        |
| <b>Total grants paid</b>  | <b>323</b>  | <b>396</b> | <b>22</b>             | <b>418</b>       | <b>408</b>       |

Grants payable to individuals may be made payable to the workplace for the benefit of the individual.

| 2018  | Grants paid |            | Staff and other costs | Year to 31/12/18 |
|---|-------------|------------|-----------------------|------------------|
|   | No          | £000       | £000                  | £000             |
| <i>Grants payable to individuals</i>                                |             |            |                       |                  |
| Travel grants and grants for attendance at meetings and conferences | 183         | 101        | 6                     | 107              |
| Summer studentships   | 12          | 32         | 3                     | 35               |
| Early career grants   | 19          | 177        | 4                     | 181              |
| <b>Total grants payable to individuals</b>                          | <b>214</b>  | <b>310</b> | <b>13</b>             | <b>323</b>       |
| <i>Grants paid to institutions:</i>                                 |             |            |                       |                  |
| Patient support grants  | 18          | 21         | 0                     | 21               |
| Public engagement grants  | 1           | 1          | 0                     | 1                |
| Undergraduate achievement award                                     | 4           | 3          | 0                     | 3                |
| Regional clinical cases grants                                      |             |            | 2                     | 2                |
| Other grants  | 32          | 57         | 1                     | 58               |
| <b>Total grants paid to institutions:</b>                           | <b>55</b>   | <b>82</b>  | <b>3</b>              | <b>85</b>        |
| <b>Total grants paid</b>  | <b>269</b>  | <b>392</b> | <b>16</b>             | <b>408</b>       |

## **SOCIETY FOR ENDOCRINOLOGY**

NOTES TO THE ACCOUNTS FOR THE YEAR ENDED 31 DECEMBER 2019 (cont.)

### **9) Support costs**

Support costs are all directly attributable to charitable activities as shown in note 8 and are made up as follows:

|                              | <b>Year to<br/>31/12/19<br/>£000</b> | <b>Year to<br/>31/12/18<br/>£000</b> |
|------------------------------|--------------------------------------|--------------------------------------|
| Governance                   | 98                                   | 83                                   |
| Finance and administration   | 354                                  | 122                                  |
| Information technology       | 125                                  | 70                                   |
| Marketing and communications | 32                                   | 3                                    |
| Human resources              | 146                                  | 35                                   |
| Executive                    | 57                                   | 102                                  |
| <b>Total</b>                 | <b>812</b>                           | <b>415</b>                           |

### **10) Net (Expenditure) / Income**

This is stated after charging:

|                                | <b>Year to<br/>31/12/19<br/>£000</b> | <b>Year to<br/>31/12/18<br/>£000</b> |
|--------------------------------|--------------------------------------|--------------------------------------|
| Depreciation and amortisation  | 109                                  | 114                                  |
| Auditor's remuneration:        |                                      |                                      |
| Audit services                 | 17                                   | 17                                   |
| Accountancy and other services | 3                                    | 11                                   |

### **11) Staff costs**

Staff costs during the year amounted to:

|                       | <b>Year to<br/>31/12/19<br/>£</b> | <b>Year to<br/>31/12/18<br/>£</b> |
|-----------------------|-----------------------------------|-----------------------------------|
| Salaries              | 2,544,022                         | 2,526,177                         |
| Social security costs | 248,982                           | 243,939                           |
| Other pension costs   | 265,947                           | 275,196                           |
|                       | <b>3,058,951</b>                  | <b>3,045,312</b>                  |

## **SOCIETY FOR ENDOCRINOLOGY**

### NOTES TO THE ACCOUNTS FOR THE YEAR ENDED 31 DECEMBER 2019 (cont.)

---

#### **11) Staff costs (cont.)**

The number of employees whose remuneration was within the bands stated was as follows:

|                     | <b>Year to<br/>31/12/19<br/>Number</b> | <b>Year to<br/>31/12/18<br/>Number</b> |
|---------------------|--|--|
| £60,001 - £70,000   | 2                                      | 3                                      |
| £70,001 - £80,000   | 2                                      | 1                                      |
| £80,001 - £90,000   | -                                      | 1                                      |
| £90,001 - £100,000  | 1                                      | -                                      |
| £100,001 - £110,000 | -                                      | 1                                      |
| £140,001 - £150,000 | -                                      | 1                                      |
| £160,001 - £170,000 | 1                                      | -                                      |

---

The average number of employees analysed by function was:

|                       | <b>Year to<br/>31/12/19<br/>Number</b> | <b>Year to<br/>31/12/18<br/>Number</b> |
|-----------------------|--|--|
| Charitable activities | 63                                     | 55                                     |
| Administration        | 25                                     | 25                                     |
|                       | <hr/>                                  | <hr/>                                  |
|                       | 88                                     | 80                                     |

---

The total remuneration, benefits and pension contributions paid in respect of key management personnel in the year was £800,898 (2018: £758,399).

The members of the Council of Management received no remuneration for their services (2018: £nil).

Travel and subsistence expenses were reimbursed to 14 current and past member of the Council of Management totalling £8,593 (2018: 14 members, £6,599).

The Society holds indemnity insurance to indemnify the Society, its employees and agents in respect of neglect and default on their part. The cost of insurance was £25,970 (2018: £26,470).



**SOCIETY FOR ENDOCRINOLOGY**

NOTES TO THE ACCOUNTS FOR THE YEAR ENDED 31 DECEMBER 2019 (cont.)

**12) Intangible assets**

|                       | <b>Group and Company</b>   |             |
|-----------------------|----------------------------|-------------|
|                       | <b>Office<br/>software</b> | <b>2018</b> |
|                       | <b>£000</b>                | <b>£000</b> |
| <b>Cost:</b>          |                            |             |
| 1 January 2019        | 218                        | 209         |
| Additions             | 35                         | 9           |
| Adjustments           | -                          | -           |
| 31 December 2019      | <u>253</u>                 | <u>218</u>  |
| <b>Amortisation</b>   |                            |             |
| 1 January 2019        | 166                        | 126         |
| Adjustments           | -                          | -           |
| Charge for the year   | 33                         | 40          |
| 31 December 2019      | <u>199</u>                 | <u>166</u>  |
| <b>Net Book Value</b> |                            |             |
| 31 December 2019      | <u>54</u>                  | <u>52</u>   |

**SOCIETY FOR ENDOCRINOLOGY**

NOTES TO THE ACCOUNTS FOR THE YEAR ENDED 31 DECEMBER 2019 (cont.)

**13) Tangible assets**

|                         | Freehold<br>land and<br>buildings | Fixtures<br>and<br>fittings | Office<br>equipment | Company<br>total | Development<br>costs | Group<br>total |
|-------------------------|-----------------------------------|-----------------------------|---------------------|------------------|----------------------|----------------|
|                         | £000                              | £000                        | £000                | £000             | £000                 | £000           |
| <b>Cost:</b>            |                                   |                             |                     |                  |                      |                |
| 1 January 2019          | 1,767                             | 269                         | 399                 | <b>2,435</b>     | 37                   | <b>2,472</b>   |
| Additions               | -                                 | 13                          | 44                  | <b>57</b>        | -                    | <b>57</b>      |
| Disposals               | -                                 | -                           | -                   | -                | -                    | -              |
| Adjustments             | -                                 | -                           | -                   | -                | -                    | -              |
| 31 December 2019        | <b>1,767</b>                      | <b>282</b>                  | <b>443</b>          | <b>2,492</b>     | <b>37</b>            | <b>2,529</b>   |
| <b>Depreciation</b>     |                                   |                             |                     |                  |                      |                |
| 1 January 2019          | 29                                | 79                          | 347                 | <b>455</b>       | 37                   | <b>492</b>     |
| Charge for the year     | 36                                | 18                          | 21                  | <b>75</b>        | -                    | <b>75</b>      |
| Eliminated on disposals | -                                 | -                           | -                   | -                | -                    | -              |
| Adjustments             | -                                 | -                           | -                   | -                | -                    | -              |
| 31 December 2019        | <b>65</b>                         | <b>97</b>                   | <b>368</b>          | <b>530</b>       | <b>37</b>            | <b>567</b>     |
| <b>Net Book Value</b>   |                                   |                             |                     |                  |                      |                |
| 31 December 2019        | <b>1,702</b>                      | <b>185</b>                  | <b>75</b>           | <b>1,962</b>     | -                    | <b>1,962</b>   |
| 31 December 2018        | <b>1,738</b>                      | <b>190</b>                  | <b>52</b>           | <b>1,980</b>     | -                    | <b>1,980</b>   |

**SOCIETY FOR ENDOCRINOLOGY**

NOTES TO THE ACCOUNTS FOR THE YEAR ENDED 31 DECEMBER 2019 (cont.)

**14) Listed Investments**

|                                      | <b>Group and company</b> |              |
|--------------------------------------|--------------------------|--------------|
|                                      | <b>2019</b>              | <b>2018</b>  |
|                                      | <b>£000</b>              | <b>£000</b>  |
| Market value at 1 January 2019:      | 3,310                    | 2,642        |
| Additions                            | 879                      | 1,959        |
| Disposals                            | (831)                    | (1,045)      |
| Movement in cash awaiting investment | -                        | -            |
| Net unrealised investment gains      | 384                      | (246)        |
| Market value at 31 December 2019     | <u>3,742</u>             | <u>3,310</u> |

|  | <b>Group and company</b> |              |
|--|--------------------------|--------------|
|  | <b>2019</b>              | <b>2018</b>  |
|  | <b>£000</b>              | <b>£000</b>  |
| The market value at 31 December 2019 comprises |                          |              |
| Listed investments                             | 3,742                    | 3,310        |
| Cash awaiting investment                       | 72                       | 75           |
|  | <u>3,814</u>             | <u>3,385</u> |

The historical cost of investments was £3,328,193 (31 December 2018: £3,169,632).

**15) Debtors**

|                                 | <b>2019</b>  |                | <b>2018</b>  |                |
|---------------------------------|--------------|----------------|--------------|----------------|
|                                 | <b>Group</b> | <b>Charity</b> | <b>Group</b> | <b>Charity</b> |
|                                 | <b>£000</b>  | <b>£000</b>    | <b>£000</b>  | <b>£000</b>    |
| Trade and other debtors         | 1,284        | 32             | 2,340        | 34             |
| Amounts due from subsidiary     | -            | -              | -            | 580            |
| Prepayments and accrued income  | 561          | 184            | 507          | 164            |
| Derivative Asset                | 77           | -              | -            | -              |
| Other taxes and social security | 2            | -              | -            | -              |
|                                 | <u>1,924</u> | <u>216</u>     | <u>2,847</u> | <u>778</u>     |

**SOCIETY FOR ENDOCRINOLOGY**

## NOTES TO THE ACCOUNTS FOR THE YEAR ENDED 31 DECEMBER 2019 (cont.)

**16) Cash at bank and in hand**

|                        | 2019         |              | 2018         |            |
|------------------------|--------------|--------------|--------------|------------|
|                        | Group        | Charity      | Group        | Charity    |
|                        | £000         | £000         | £000         | £000       |
| Bank current accounts  | 1,024        | 36           | 1,178        | 22         |
| Monies held on deposit | 1,182        | 967          | 489          | 311        |
| Petty cash             | 3            | -            | 2            | -          |
|                        | <b>2,209</b> | <b>1,003</b> | <b>1,669</b> | <b>333</b> |

The Group balances include funds held in respect of the activities of clients of the trading subsidiary.

**17) Creditors: amounts falling due within one year**

|                                 | 2019         |            | 2018         |            |
|---------------------------------|--------------|------------|--------------|------------|
|                                 | Group        | Charity    | Group        | Charity    |
|                                 | £000         | £000       | £000         | £000       |
| Bank Loans                      | 37           | 37         | 44           | 44         |
| Trade creditors                 | 225          | 217        | 243          | 127        |
| Amounts due to subsidiary       | -            | 27         | -            | -          |
| Clients' accounts               | 339          | -          | 360          | -          |
| Deferred income                 | 1,256        | 122        | 1,496        | 126        |
| Other taxes and social security | 67           | 67         | 190          | 192        |
| Other creditors and accruals    | 1,453        | 225        | 1,822        | 311        |
|                                 | <b>3,377</b> | <b>695</b> | <b>4,155</b> | <b>800</b> |

| Deferred income:                    | 2019         |            | 2018         |            |
|-------------------------------------|--------------|------------|--------------|------------|
|                                     | Group        | Charity    | Group        | Charity    |
|                                     | £000         | £000       | £000         | £000       |
| Deferred income at 1 January 2019   | 1,496        | 126        | 2,098        | 104        |
| Resources deferred in the year      | 1,256        | 122        | 1,496        | 126        |
| Amounts taken to income in the year | (1,496)      | (126)      | (2,098)      | (104)      |
| Deferred income at 31 December 2019 | <b>1,256</b> | <b>122</b> | <b>1,496</b> | <b>126</b> |

Deferred income largely represents 2020 journal subscription income received during 2019.

# SOCIETY FOR ENDOCRINOLOGY

## NOTES TO THE ACCOUNTS FOR THE YEAR ENDED 31 DECEMBER 2019 (cont.)

The repayment schedule for the remaining balance on the long term loan is as follows:

|                          | Group and company |              |
|--------------------------|-------------------|--------------|
|                          | 2019              | 2018         |
|                          | £000              | £000         |
| Loan repayment year 1    | 37                | 44           |
| Loan repayment years 2-5 | 148               | 176          |
| Loan repayment years 5+  | 664               | 854          |
|                          | <b>849</b>        | <b>1,074</b> |

### 18) Restricted funds

|                         | Balance at 1 January 2019 | Movement in resources |                  | Transfer between funds | Investment gains/(losses) | Balance at 31 December 2019 |
|-------------------------|---------------------------|-----------------------|------------------|------------------------|---------------------------|-----------------------------|
|                         | £000                      | Income £000           | Expenditure £000 | £000                   | £000                      | £000                        |
| CaHASE Fund             | 1                         | -                     | -                | 2                      | -                         | 3                           |
| Anti-Thyroid Drug Study | 13                        | -                     | 5                | -                      | -                         | 8                           |
| Marjorie Robinson Fund  | 343                       | 10                    | 2                | (20)                   | 28                        | 359                         |
|                         | <b>357</b>                | <b>10</b>             | <b>7</b>         | <b>(18)</b>            | <b>28</b>                 | <b>370</b>                  |

| 2018                   | Balance at 1 January 2018 | Movement in Resources |                  | Transfer between funds | Investment gains/(losses) | Balance at 31 December 2018 |
|------------------------|---------------------------|-----------------------|------------------|------------------------|---------------------------|-----------------------------|
|                        | £000                      | Income £000           | Expenditure £000 | £000                   | £000                      | £000                        |
| Acromegaly Fund        | 14                        | -                     | (14)             | -                      | -                         | -                           |
| CaHASE Fund            | 1                         | -                     | -                | -                      | -                         | 1                           |
| Pituitary Apoplexy     | 3                         | -                     | (3)              | -                      | -                         | -                           |
| Graves' Disease        | 3                         | -                     | (3)              | -                      | -                         | -                           |
| Transition Study       | 1                         | -                     | (1)              | -                      | -                         | -                           |
| Anti-Thyroid Drug      | 15                        | -                     | (2)              | -                      | -                         | 13                          |
| Marjorie Robinson Fund | 306                       | 9                     | (3)              | (20)                   | 51                        | 343                         |
|                        | <b>343</b>                | <b>9</b>              | <b>(26)</b>      | <b>(20)</b>            | <b>51</b>                 | <b>357</b>                  |

## SOCIETY FOR ENDOCRINOLOGY

### NOTES TO THE ACCOUNTS FOR THE YEAR ENDED 31 DECEMBER 2019 (cont.)

The CaHASE fund is used to run a project which aims to provide further understanding of the rare disease called congenital adrenal hyperplasia.

The Anti Thyroid Drug Study fund is used to finance a national survey of patients with anti-thyroid drug (ATD) associated agranulocytosis and fulminant hepatotoxicity.

Miss Robinson left a legacy to the Charity to provide for research into pituitary and/or adrenal disease. The Trustees have established a policy to utilise the Marjorie Robinson fund to finance up to two early career grants in this field each year.

#### 19) Unrestricted funds

|                        | Balance<br>at 1<br>January<br>2019<br>£000 | Movement in<br>resources<br>Income Expenditure<br>£000 | Transfer<br>between<br>funds<br>£000 | Investment<br>gains/<br>(losses)<br>£000 | Balance at<br>31<br>December<br>2019<br>£000 |
|------------------------|--|--|--------------------------------------|--|--|
| Main Fund              | 4,753                                      | 1,350  | (2,156)                              | 868                                      | 5,172  |
| Bioscientifica Limited | 49   | 5,172  | (4,139)                              | (850)                                    | 232  |
|                        | <u>4,802</u>                               | <u>6,522</u>   | <u>(6,295)</u>                       | <u>18</u>                                | <u>5,404</u>                                 |

Bioscientifica Limited profits of £1,098k were transferred to the Main Fund as gift aid.

| 2018                   | Balance<br>at 1<br>January<br>2018<br>£000 | Movement in<br>resources<br>Income Expenditure<br>£000 | Transfer<br>between<br>funds<br>£000 | Investment<br>gains/<br>(losses)<br>£000 | Balance at<br>31<br>December<br>2018<br>£000 |
|------------------------|--|--|--------------------------------------|--|--|
| Main Fund              | 5,075                                      | 996  | (1,803)                              | 782                                      | 4,753  |
| Bioscientifica Limited | 49   | 5,463  | (4,701)                              | (762)                                    | 49   |
|                        | <u>5,124</u>                               | <u>6,459</u>   | <u>(6,504)</u>                       | <u>20</u>                                | <u>4,802</u>                                 |

**SOCIETY FOR ENDOCRINOLOGY**

NOTES TO THE ACCOUNTS FOR THE YEAR ENDED 31 DECEMBER 2019 (cont.)

**20) Analysis of group net assets between funds**

|                          | Unrestricted<br>funds | Restricted<br>Funds | 2019         | 2018         |
|--------------------------|-----------------------|---------------------|--------------|--------------|
|                          | £000                  | £000                | £000         | £000         |
| Intangible fixed assets  | 54                    |                     | 54           | 52           |
| Tangible fixed assets    | 1,962                 |                     | 1,962        | 1,980        |
| Listed Investments       | 3,438                 | 376                 | 3,814        | 3,385        |
| Assets held for sale     | 0                     |                     | 0            | 411          |
| Debtors                  | 1,930                 | (6)                 | 1,924        | 2,847        |
| Cash at bank and in hand | 2,209                 |                     | 2,209        | 1,669        |
| Creditors                | (3,394)               |                     | (3,394)      | (4,155)      |
| Long term loans          | (795)                 |                     | (795)        | (1,030)      |
|                          | <b>5,404</b>          | <b>370</b>          | <b>5,774</b> | <b>5,159</b> |

| 2018                     | Unrestricted<br>funds | Restricted<br>Funds | 2018         |
|--------------------------|-----------------------|---------------------|--------------|
|                          | £000                  | £000                | £000         |
| Intangible fixed assets  | 52                    |                     | 52           |
| Tangible fixed assets    | 1,980                 |                     | 1,980        |
| Listed Investments       | 3,033                 | 352                 | 3,385        |
| Assets held for sale     | 411                   |                     | 411          |
| Debtors                  | 2,842                 | 5                   | 2,847        |
| Cash at bank and in hand | 1,669                 |                     | 1,669        |
| Creditors                | (4,155)               |                     | (4,155)      |
| Long term loans          | (1,030)               |                     | (1,030)      |
|                          | <b>4,802</b>          | <b>357</b>          | <b>5,159</b> |

**21) Transfer between funds**

|   | 2019   | 2018   |
|---|--------|--------|
|   | £      | £      |
| During the year the following transfers were made between funds:  |        |        |
| <i>From the Main Fund to:</i>   |        |        |
| CaHASE Fund to contribute to the support costs of the fund  | 2,500  | -      |
| <i>From the Marjorie Robinson Fund to:</i>  |        |        |
| Main Fund to provide early career research grants (2018: Grants for research into pituitary and/or adrenal disease) | 20,000 | 20,000 |

**22) Capital commitments**

There were no capital commitments authorised but not contracted at the year-end (31 December 2018: £120k).

**23) Related party transactions**

The charity has taken advantage of the exemption available under FRS 102 paragraph 33.1A not to disclose transactions entered into between wholly owned members of the same group.

Where members of the Council of Management are in a position to exercise significant influence they declare their interest and exclude themselves from any relevant discussions. In extreme cases, where this approach is not sufficient, discussions are held with the individual regarding standing down from one of the organisations.

No other related party transactions have occurred in the year.

**24) Impact of Covid-19**

In light of the emergence and spread of the coronavirus (COVID-19), the Trustees are monitoring the situation very closely to assess the potential impact on Society and Group operations. As the spread of the virus and associated measures to restrict its impact took place in the UK and Europe in February and March 2020 the effects of pandemic, are considered to be a non-adjusting post balance sheet event for the company.

The Society is likely to see a limited effect on its own operations in the year to 31 December 2020, however the activities of its trading subsidiary, Bioscientifica, are expected to be more affected, which will have an impact on Group financial performance for this period. Gift Aid from Bioscientifica to the Society is likely to be materially reduced compared to original expectations for 2020, and will lead to the Society utilising its accumulated reserves to support current year activities.

The Society is also likely to see an impact on the changes in valuation of investments held in its investments portfolio but the full impact is unknown. At 19 June 2020, the market value of the investment portfolio was £15k higher than reported at 31 December 2019.

There is not expected to be a material impact on the market value of the Society's head office building.

The Trustees have prepared cash flow forecasts to plan for the above, including any reasonably foreseeable mitigating factors and the Trustees are comfortable that the Society can continue as a going concern for the foreseeable future.



**SOCIETY FOR ENDOCRINOLOGY**

## MAIN FUND

## INCOME AND EXPENDITURE ACCOUNT FOR YEAR ENDED 31 DECEMBER 2019

|   |      | Year ended 31/12/19 |         | Year ended 31/12/2018 |         |
|---|------|---------------------|---------|-----------------------|---------|
|   | Note | £000                | £000    | £000                  | £000    |
| <b>Income from activities:</b>  |      |                     |         |                       |         |
| Membership subscriptions  |      | 165                 |         | 146                   |         |
| Event income  |      | 695                 |         | 547                   |         |
| Royalties receivable  |      | 170                 |         | 159                   |         |
| Advertising income  |      | 2                   |         | 1                     |         |
| Sundry income   |      | 33                  |         | 51                    |         |
|   |      |                     | 1,065   |                       | 904     |
| <b>Expenditure on activities:</b>   |      |                     |         |                       |         |
| Divisional Salaries   |      | 323                 |         | 301                   |         |
| Publishing costs  |      | 19                  |         | 21                    |         |
| Venue and catering costs  |      | 419                 |         | 393                   |         |
| Bioscientifica management fees  |      | 215                 |         | 157                   |         |
| Programmes, abstracts and handbooks   |      | 27                  |         | 20                    |         |
| Expenses  |      | 103                 |         | 142                   |         |
| Marketing   |      | 17                  |         | 22                    |         |
| Other direct expenses   |      | 82                  |         | 86                    |         |
| Grants  |      | 394                 |         | 392                   |         |
|   |      |                     | 1,599   |                       | 1,534   |
| <b>Deficit from activities</b>  |      |                     | (534)   |                       | (630)   |
| <b>Overheads</b>  |      |                     |         |                       |         |
| Salaries  |      | 465                 |         | 176                   |         |
| Other staff costs   |      | 160                 |         | 95                    |         |
| Staff expenses  |      | 33                  |         | 30                    |         |
| Premises costs  |      | 176                 |         | 192                   |         |
| Insurance   |      | 28                  |         | 30                    |         |
| Professional fees   |      | 17                  |         | 18                    |         |
| Investment manager's fees   |      | 17                  |         | 18                    |         |
| Printing, postage, stationery and telephone   |      | 5                   |         | 8                     |         |
| Depreciation  |      | 109                 |         | 110                   |         |
| Loss on disposal of fixed assets  |      | (187)               |         | -                     |         |
| Marketing   |      | 1                   |         | 4                     |         |
| Bank and credit card charges  |      | 33                  |         | 21                    |         |
| Sundry office expenses  |      | 33                  |         | 29                    |         |
| Recharged   |      | (272)               |         | (301)                 |         |
|   |      |                     | 618     |                       | 430     |
| <b>Deficit from Main Fund before investment income and gains on investments (carried forward)</b> |      |                     | (1,152) |                       | (1,060) |

**SOCIETY FOR ENDOCRINOLOGY**

## MAIN FUND

## INCOME AND EXPENDITURE ACCOUNT FOR YEAR ENDED 31 DECEMBER 2019

|   | Note | Year ended 31/12/19 |                   | Year ended 31/12/2018 |                     |
|---|------|---------------------|-------------------|-----------------------|---------------------|
|   |      | £000                | £000              | £000                  | £000                |
| <b>Deficit from Main Fund before investment income and gains on investments (brought forward)</b> |      |                     | (1,152)           |                       | (1,060)             |
| Income from listed investments  |      | 98                  |                   | 95                    |                     |
| Bank deposit interest   |      | -                   |                   | -                     |                     |
| Gift aid from Bioscientifica Limited  |      | 1,098               |                   | 920                   |                     |
|   |      |                     | <u>1,196</u>      |                       | <u>1,015</u>        |
| <b>(Deficit) / Surplus prior to transfers</b>   |      |                     | <u>44</u>         |                       | <u>(45)</u>         |
| Transfers from / (to) designated funds  |      |                     | <u>18</u>         |                       | <u>20</u>           |
| Surplus from unrestricted fund before gains on investments  |      |                     | 62                |                       | (25)                |
| Net gains/(losses) on investments   |      |                     | <u>357</u>        |                       | <u>(297)</u>        |
| <b>Total surplus / (deficit) for the year</b>   |      |                     | <u><u>419</u></u> |                       | <u><u>(322)</u></u> |

**SOCIETY FOR ENDOCRINOLOGY**  
**MAIN FUND**  
**BALANCE SHEET AT 31 DECEMBER 2019**

|  |      | 2019         |              | 2018         |              |
|--|------|--------------|--------------|--------------|--------------|
|  | Note | £000         | £000         | £000         | £000         |
| <b>Fixed Assets</b>                          |      |              |              |              |              |
| Intangible assets                            |      |              | 54           |              | 52           |
| Tangible assets                              |      |              | 1,962        |              | 1,980        |
| Listed investments                           |      |              | 3,439        |              | 3,033        |
| Investment in Bioscientifica Limited         |      |              | 1            |              | 1            |
|  |      |              | <u>5,456</u> |              | <u>5,066</u> |
| <b>Current assets</b>                        |      |              |              |              |              |
| Debtors and prepayments                      |      | 216          |              | 583          |              |
| Bioscientifica Limited                       |      | (27)         |              | 676          |              |
| Cash at bank and in hand                     |      | 1,003        |              | 333          |              |
|  |      | <u>1,192</u> |              | <u>1,592</u> |              |
| <b>Current liabilities</b>                   |      |              |              |              |              |
| Income in advance                            |      | 122          |              | 126          |              |
| Creditors and accruals                       |      | 564          |              | 700          |              |
| Long term loans                              |      | 795          |              | 1,075        |              |
| Marjorie Robinson Fund                       |      | (17)         |              | (9)          |              |
| CaHASE Fund                                  |      | 3            |              | 1            |              |
| Anti Thyroid Drug Study                      |      | 8            |              | 13           |              |
|  |      | <u>1,475</u> |              | <u>1,906</u> |              |
| <b>Net Current Assets</b>                    |      |              | <u>(283)</u> |              | <u>(314)</u> |
| <b>Total assets less current liabilities</b> |      |              | <u>5,173</u> |              | <u>4,754</u> |
| <b>Financed by:</b>                          |      |              |              |              |              |
| Unrestricted Fund                            | 19   |              | <u>5,173</u> |              | <u>4,754</u> |

**SOCIETY FOR ENDOCRINOLOGY**

## MARJORIE ROBINSON FUND

## INCOME AND EXPENDITURE ACCOUNT FOR YEAR ENDED 31 DECEMBER 2019

|  |  | Year ended<br>31/12/19<br>£000 | Year ended<br>31/12/18<br>£000 |
|--|--|--------------------------------|--------------------------------|
| Listed investment income                     |  | 10                             | 9                              |
| Interest received                            |  | -                              | -                              |
|  |  | <u>10</u>                      | <u>9</u>                       |
| <b>Expenditure on activities:</b>            |  |                                |                                |
| Grants paid                                  |  | 21                             | 20                             |
| Investment managers' fees                    |  | 2                              | 2                              |
|  |  | <u>23</u>                      | <u>22</u>                      |
| Deficit before gains /(losses) on investment |  | (13)                           | (13)                           |
| Gains / (losses) on investments              |  | 28                             | 51                             |
| <b>Surplus for the year</b>                  |  | <u>15</u>                      | <u>38</u>                      |

**Balance sheet at 31 December 2019**

|                             |    | 2019       | 2018       |
|-----------------------------|----|------------|------------|
| <b>Fixed Assets</b>         |    |            |            |
| Listed investments          |    | 375        | 351        |
| <b>Current assets</b>       |    |            |            |
| Main Fund – current account |    | (17)       | (9)        |
| <b>Net assets</b>           |    | <u>358</u> | <u>342</u> |
| <b>Financed by:</b>         |    |            |            |
| Marjorie Robinson Fund      | 18 | <u>358</u> | <u>342</u> |

**SOCIETY FOR ENDOCRINOLOGY**

CaHASE FUND

INCOME AND EXPENDITURE ACCOUNT FOR YEAR ENDED 31 DECEMBER 2019

|   |  | Year ended<br>31/12/19<br>£000 | Year ended<br>31/12/18<br>£000 |
|---|--|--------------------------------|--------------------------------|
| <b>Income from activities:</b>          |  |                                |                                |
| Grants received                         |  | 3                              | -                              |
|   |  | <u>3</u>                       | <u>-</u>                       |
| <b>Expenditure on activities:</b>       |  |                                |                                |
| General expenses                        |  | -                              | -                              |
| Management charge                       |  | -                              | -                              |
|   |  | <u>-</u>                       | <u>-</u>                       |
| <b>Surplus / (Deficit) for the year</b> |  | <u>3</u>                       | <u>-</u>                       |

**Balance sheet at 31 December 2019**

|                             |    | 2019     | 2018     |
|-----------------------------|----|----------|----------|
| <b>Current assets</b>       |    |          |          |
| Main Fund – current account |    | 3        | 1        |
|                             |    | <u>3</u> | <u>1</u> |
| <b>Net current assets</b>   |    | <u>3</u> | <u>1</u> |
| <b>Financed by:</b>         |    |          |          |
| CaHASE Fund                 | 18 | 3        | 1        |
|                             |    | <u>3</u> | <u>1</u> |

**SOCIETY FOR ENDOCRINOLOGY**

## ANTI-THYROID DRUG STUDY

## INCOME AND EXPENDITURE ACCOUNT FOR YEAR ENDED 31 DECEMBER 2019

|  |    | Year ended<br>31/12/19<br>£000 | Year ended<br>31/12/18<br>£000 |
|--|----|--------------------------------|--------------------------------|
| <b>Income from activities:</b>           |    |                                |                                |
| Grants received                          |    | -                              | -                              |
|  |    | <u>-</u>                       | <u>-</u>                       |
| <b>Expenditure on activities:</b>        |    |                                |                                |
| General expenses                         |    | -                              | -                              |
| Management charge                        |    | 5                              | 2                              |
|  |    | <u>5</u>                       | <u>2</u>                       |
| <b>Surplus / (Deficit) for the year</b>  |    | <u>(5)</u>                     | <u>(2)</u>                     |
| <b>Balance sheet at 31 December 2019</b> |    |                                |                                |
|  |    | <b>2019</b>                    | <b>2018</b>                    |
| <b>Current assets</b>                    |    |                                |                                |
| Main Fund – current account              |    | 8                              | 13                             |
|  |    | <u>8</u>                       | <u>13</u>                      |
| <b>Net current assets</b>                |    | <u>8</u>                       | <u>13</u>                      |
| <b>Financed by:</b>                      |    |                                |                                |
| Transition Study Fund                    | 19 | 8                              | 13                             |
|  |    | <u>8</u>                       | <u>13</u>                      |